I’m not 100% sure of policy concerning posting a

I’m not 100% sure of policy concerning posting about other companies on this board. This post is on a related subject, and is a related question to Cytodyn’s Covid manufacturing strategies.

My question(s) is(are):

Is Cytodyn pursuing “outside of the box” manufacturing technologies like the one written about below? I haven’t heard of any.

Do members of this board have ideas kicking around that might be worthy of discussion around other scalable manufacturing technologies like written below?

And is it likely that the technology written below could work for a monoclonal antibody?

IBIO inc was funded by DARPA to development their technology. It was begun for preparedness for epidemics and pandemics. In a nutshell, it uses a relative of the tobacco plant to produce vaccines and other therapeutics on a large scale. The plant IS the bioreactor. They claim a yearly capacity of 500 million doses.

Sorry, I couldn’t get a real link to paste h in this post.

Thanks, chazzleD

https://www.globenewswire.com/news-release/20...tPharming-

Quote:

“That scalability links directly to the modular technology behind our FastPharming Manufacturing System, which uses a relative of the tobacco plant as the 'bioreactor' to produce biopharmaceuticals,” continued Mr. Isett. “So, the amount of product generated by a single plant is consistent from research- to commercial-scale, and scale-up is achieved by simply growing thousands more plants within our 130,000 square foot facility. This is real innovation in the manufacture of biopharmaceuticals, thus our significant synergy with the NIIMBL community.”

Quote:

Mr. Isett added, “Given Manufacturing USA’s increasing COVID-19 response efforts, we are honored to expand our involvement by joining NIIMBL as American companies with enabling technologies work together to fight the pandemic. To that end, in addition to work on our proprietary VLP vaccine, we are ready to make the FastPharming System available to other COVID-19 vaccine and therapeutic developers on a contract manufacturing basis to help speed their products to market as well.”